Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04091438 · ClinicalTrials.gov registry record · Phase 1
A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04091438 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 28 participants.
The verdict
NCT04091438, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of administering a single intravenous (IV) infusion dose of TAK-925 to adult participants with idiopathic hypersomnia (IH).
Interventions
- DRUG TAK-925
- DRUG TAK-925 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-01-26 |
| Est. Completion | 2020-11-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04091438
The ClinicalTrials.gov registry entry for NCT04091438 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-925 is the first listed.
NCT04091438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04091438 about?
NCT04091438 is a clinical study titled "A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia". The purpose of this study is to evaluate the safety and tolerability of administering a single intravenous (IV) infusion dose of TAK-925 to adult participants with idiopathic hypersomnia (IH).
What is the current status of trial NCT04091438?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2020-01-26. Estimated completion is 2020-11-23.
What interventions are being tested in trial NCT04091438?
The interventions under investigation include: TAK-925 (DRUG), TAK-925 Placebo (DRUG).
Who is sponsoring clinical trial NCT04091438?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.